HFA News & Notes

HFA Observes National Hepatitis Awareness Month

HFA Observes National Hepatitis Awareness Month FOR IMMEDIATE RELEASE: May 3, 2012 Contact: Richard Pezzillo [...] Read More >>

Community Pharmacists Lose Bid to Immediately Block Express Scripts-Medco Deal

By Rebecca Adams, CQ HealthBeat Associate Editor A federal judge has denied the request of a group of community [...] Read More >>

People with Bleeding Disorders and HCV

Link to Access HCV Therapy Site Friends and supporters, We should all be enormously encouraged by the increasing [...] Read More >>

Contact Info

Hemophilia Federation of America
210 7th St. SE, Suite 200B
Washington D.C., 20003
800.230.9797
202.675.6984
202.675.6983

© 2011 Hemophilia Federation of America · Board of Directors Only · BB Admin Only · Privacy & Legal

News & Notes

Find more information about:
or search by other:

High Costs Of Specialty Drugs

August 23rd, 2011 by Katie Whittle

By Julie Appleby KHN Staff Writer Aug 22, 2011 This story was produced in collaboration with For Judy Ariba, one of the most harrowing moments in her battle against a rare form of leukemia occurred after she had already endured a long hospital stay and grueling chemotherapy: Her bill for a prescription cancer drug jumped from $10 to $1,700 a month. After Judy Ariba’s former employer switched to a new health plan that required ...

(Keep Reading)

HFA Press Release: Inaugural Bike Ride

August 22nd, 2011 by Katie Whittle

FOR IMMEDIATE RELEASE: August 16, 2011 Hemophilia Federation of America launches Inaugural Bike Ride Washington DC:  The Hemophilia Federation of America (HFA) launches inaugural bike ride, “Gears for Good”, September 15 - 17, 2011.  A three day 156 mile ride departing West Virginia ...

(Keep Reading)

NEWS/UPDATE: BIOGEN IDEC AND SWEDISH ORPHAN BIOVITRUM PRESENT DATA ON LONG-LASTING RECOMBINANT FACTOR VIII THERAPY AT INTERNATIONAL SOCIETY ON THROMBOSIS AND HAEMOSTASIS MEETING

August 10th, 2011 by Katie Whittle

Biogen Idec and Swedish Orphan Biovitrum Present Data on Long-Lasting Recombinant Factor VIII Therapy at International Society on Thrombosis and Haemostasis Meeting --Results Show Potential to Significantly Reduce the Burden of Treatment for People with Hemophilia A-- KYOTO, Japan, Jul 26, 2011 ...

(Keep Reading)

Blood test can identify fetal sex as early as 7 weeks gestation

August 9th, 2011 by Katie Whittle

August 9, 2011 Fetal sex can be determined reliably with a non-invasive genetic test as early as 7 weeks into a pregnancy, according to a new meta-analysis published this week in the Journal of the American Medical Association. The results of ...

(Keep Reading)

CSL Behring Donates von Willebrand Factor / Factor VIII Donation to World Federation of Hemophilia

August 5th, 2011 by sswindle

Company gives more than 1 million units of VWD medication via WFH’s Global Alliance for Progress program as part of its 3-year commitment to the organization King of Prussia, PA – July 18, 2011 – CSL Behring has donated more ...

(Keep Reading)

BIOGEN IDEC AND SWEDISH ORPHAN BIOVITRUM

August 5th, 2011 by sswindle

KYOTO, Japan – July 26, 2011 BIOGEN IDEC AND SWEDISH ORPHAN BIOVITRUM present data On LONG-LASTING RECOMBINANT factor VIII therapy at international society on thrombosis and haemostasis meeting --Results Show Potential to Significantly Reduce the Burden of Treatment for People with Hemophilia ...

(Keep Reading)

Dads In Action

August 2nd, 2011 by crucedesign

School is just around the corner! Educate your child's school about bleeding disorders!

Attorneys General Back Missouri Lt. Gov. in Challenge to Health Care Law

August 2nd, 2011 by Eboni Morris

By Jane Norman, CQ HealthBeat Associate Editor Attorneys general from 21 states filed a brief Tuesday backing a legal challenge to the health care law that’s being pursued by Missouri’s lieutenant governor. The brief includes state officials who are the plaintiffs in ...

(Keep Reading)

Baxter Voluntary Recall

July 28th, 2011 by Katie Whittle

Notice: Baxter is voluntarily recalling one (1) lot of RECOMBINATE , product code 1501594, NDC Number 0944-2833-10, lot number TRA09834AB, with an expiry date of January 28, 2012. This action is being taken as a precautionary measure after a retrospective review ...

(Keep Reading)

BAXTER PRESENTS PRECLINICAL DATA AT ISTH ON ITS INVESTIGATIONAL COMPOUND BAX 499 FOR POTENTIAL SUBCUTANEOUS HEMOPHILIA THERAPY AND FINAL PHASE I DATA ON RECOMBINANT VON WILLEBRAND FACTOR

July 26th, 2011 by Katie Whittle

FOR IMMEDIATE RELEASE Media Contacts Doreen Eaton, (805) 372-3417 Marie Kennedy, (805) 372-3543 Investor Contacts Mary Kay Ladone, (847) 948-3371 Clare Trachtman, (847) 948-3085 BAXTER PRESENTS PRECLINICAL DATA AT ISTH ON ITS INVESTIGATIONAL COMPOUND BAX 499 FOR POTENTIAL SUBCUTANEOUS HEMOPHILIA THERAPY AND FINAL PHASE I ...

(Keep Reading)

CSL Behring Donates von Willebrand Factor / Factor VIII Donation to World Federation of Hemophilia

July 21st, 2011 by Katie Whittle

Link to news release Company gives more than 1 million units of VWD medication via WFH’s Global Alliance for Progress program as part of its 3-year commitment to the organization King of Prussia, PA — 18 July 2011 CSL Behring has donated more ...

(Keep Reading)

So Far, Exchanges Are a ‘Mixed Bag’ for Patients, Group Says

July 6th, 2011 by Eboni Morris

By John Reichard, CQ HealthBeat Editor The health care law will disappoint many Americans if its health insurance exchanges don’t deliver decent coverage at affordable rates for consumers, including those with serious illnesses like cancer. Meeting those expectations may be difficult, judging ...

(Keep Reading)

Ohio District Court Rules in Favor of Health Care Law

July 6th, 2011 by Eboni Morris

By Jane Norman, CQ HealthBeat Associate Editor A federal district court in Ohio ruled in favor of the health care law on Tuesday, saying it was bound by a decision in favor of the law’s constitutionality made by the Circuit Court ...

(Keep Reading)